Clinical Trial: Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Esophageal Cancer
Study Type: OBSERVATIONAL
Official Title: Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Brief Summary:
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC).Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used.However, there is currently no definitive evidence comparing the efficacy of these two agents in the context of neoadjuvant therapy for ESCC.
Read more